NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Financial Results of the Company for the quarter and year ended March 31, 202311-05-2023
11-05-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Dividend Updates
Recommendation of final dividend for the financial year 2022-23.11-05-2023
NEULAND LABORATORIES LTD. - 524558 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 11, 2023 - Audited Financial Results And Recommendation Of Final Dividend For Financial Year 2022-2023
Outcome of Board Meeting held on May 11, 2023 - Audited Financial Results and recommendation of Final Dividend for financial year 2022-202311-05-2023
NEULAND LABORATORIES LTD. - 524558 - Outcome Of Board Meeting Held On May 11, 2023 - Audited Financial Results And Recommendation Of Final Dividend For Financial Year 2022-2023
Outcome of Board Meeting held on May 11, 2023 - Audited Financial Results and recommendation of Final Dividend for financial year 2022-202311-05-2023
NEULAND LABORATORIES LTD. - 524558 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Certificate(s)08-05-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call Intimation Q4 and full year FY202304-05-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Credit Rating
Announcement under Regulation 30 (LODR)- Upgrade of Credit Rating25-04-2023
NEULAND LABORATORIES LTD. - 524558 - Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2023, And; To Recommend Final Dividend, If Any, For The Financial Year Ended March 31, 2023
NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2023 ,inter alia, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2023, and; to recommend final dividend, if any, for the financial year ended March 31, 202314-04-2023
NEULAND LABORATORIES LTD. - 524558 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyNEULAND LABORATORIES LTD. 2CIN NO.L85195TG1984PLC004393 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 94.30 4Highest Credit Rating during the previous FY A 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Sarada Bhamidipati Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Abhijit Majumdar Designation: Chief Financial Officer EmailId: [email protected] Date: 13/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.13-04-2023